Akouos to Participate in Upcoming February Virtual Investor Conferences

Rhea-AI Summary

Akouos, a precision genetic medicine company focused on gene therapies for disabling hearing loss, will participate in two virtual investor conferences in February. The Cowen 2nd Annual Genetic Medicines Summit features a panel discussion on February 3, while the 11th Annual SVB Leerink Global Healthcare Conference includes a presentation by CEO Manny Simons on February 16. Both events aim to highlight advancements in genetic therapies. A live webcast will be available on Akouos's website, with an archived replay accessible for 30 days afterwards.

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:

• Cowen 2^nd Annual Genetic Medicines Summit. Panel discussion including Stacy Price, M.S., chief technical officer, titled “Hot Topics in CMC/Manufacturing of Genetic Medicines” on Thursday, February 3 at 2:00 p.m. EST
  
• 11^th Annual SVB Leerink Global Healthcare Conference 2022. Presentation by Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer, on Wednesday, February 16 at 3:00 p.m. EST
  

A live webcast of the SVB Leerink presentation will be accessible through the investors section of www.akouos.com. To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. An archived replay will be available on Akouos’s website for 30 days following the conference.

About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

When is Akouos participating in the Cowen 2nd Annual Genetic Medicines Summit?

Akouos will participate in the Cowen 2nd Annual Genetic Medicines Summit on February 3 at 2:00 p.m. EST.

Who will represent Akouos at the SVB Leerink Global Healthcare Conference?

Manny Simons, co-founder and CEO, will present at the SVB Leerink Global Healthcare Conference on February 16 at 3:00 p.m. EST.

How can I access the webcast of Akouos's presentations?

The webcast can be accessed through Akouos's investors section on their website, 15 minutes before the start time.

What is Akouos's focus in genetic medicine?

Akouos focuses on developing gene therapies to restore and improve hearing for individuals with disabling hearing loss.

What technology does Akouos use for their gene therapies?

Akouos leverages a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach in their gene therapy development.